日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Predicting cardiovascular toxicity in anti-PD-1/PD-L1 therapy: a risk factor analysis and model development

预测抗PD-1/PD-L1疗法的心血管毒性：风险因素分析和模型构建

期刊:Frontiers in Cardiovascular Medicine
影响因子:2.9
doi:10.3389/fcvm.2026.1731591
Yan, Zhihui; Wang, Juan; Sun, Jianxiu; Zhang, Run; Liu, Jia; Cao, Lihua; Zhang, Ming; Yu, Jiangtao; Hou, Helei; Zhang, Wenzhong
PD-L1
毒理研究
PD-1
发表日期：2026
文献求助 收藏

A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma

一项基于队列的多组学研究发现，eIF5B/PD-L1/CD44复合物的核转位是克服ARID1A缺陷型肺腺癌奥希替尼耐药性的靶点。

期刊:Experimental Hematology & Oncology
影响因子:13.5
doi:10.1186/s40164-024-00594-4
Sun, Dantong; Hou, Helei; Feng, Feiyue; Wu, Weizheng; Tan, Jingyu; Xie, Tongji; Liu, Jiayu; Wang, Jinsong; Qian, Haili; Li, Junling; Xing, Puyuan
T细胞
ID1
IF5
CD4
PD-L1
CD44
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Combination therapy with Chicoric acid and PD-1/PD-L1 blockade improves the immunotherapy response in patient-derived ovarian cancer xenograft model.

菊苣酸与 PD-1/PD-L1 阻断剂联合治疗可改善患者来源卵巢癌异种移植模型的免疫治疗反应

期刊:Cell Communication and Signaling
影响因子:8.9
doi:10.1186/s12964-025-02146-7
Lan Hongwei, Zhu Jingjuan, Hou Helei, Zhang Chuantao, Huo Xingfa, Zhang Yuming, Yang Fangfang, Zhou Na, Zhang Xiaochun
免疫/内分泌
卵巢癌
发表日期：2025
文献求助 收藏

Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IV(B) HER2-positive gastric cancer

对于潜在可切除的III期至IV(B)期HER2阳性胃癌患者，在术前化疗或化疗免疫疗法中加入曲妥珠单抗治疗

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2025.1624943
Zhang, Xuchen; Tian, Yulong; Wang, Huiyun; Song, Shanai; Chen, Yunqing; Liu, Ning; Zhang, Chuantao; Huang, Xiao; Jiang, Haitao; Hou, Helei
胃癌
肿瘤
肿瘤免疫
HER2
免疫/内分泌
发表日期：2025
文献求助 收藏

Combination of anlotinib with immunotherapy enhanced both anti-angiogenesis and immune response in high-grade serous ovarian cancer.

安罗替尼联合免疫疗法可增强高级别浆液性卵巢癌的抗血管生成和免疫反应

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2025.1539616
Lan Hongwei, Liu Hui, Hou Helei, Zhang Chuantao, Zhu Jingjuan, Zhou Na, Zhang Xiaochun
心血管
卵巢癌
血管生成
发表日期：2025
文献求助 收藏

ARID1A deficiency attenuates the response to EGFR-TKI treatment in lung adenocarcinoma

ARID1A缺陷会减弱肺腺癌对EGFR-TKI治疗的反应

期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2025.1582005
Yang, Fangfang; Hou, Helei; Wang, Guanqun; Fu, Guangming; Huo, Xingfa; Duan, Xueqin; Zhou, Na; Zhang, Xiaochun
肿瘤
肿瘤免疫
ID1
EGF
EGFR
发表日期：2025
文献求助 收藏

Multi-omics analysis of the dynamic role of STAR+ cells in regulating platinum-based chemotherapy responses and tumor microenvironment in serous ovarian carcinoma.

STAR+细胞在调节浆液性卵巢癌铂类化疗反应和肿瘤微环境中的动态作用的多组学分析

期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2025.1545762
Lan Hongwei, Yan Weihua, Huang Xiao, Cui Jiali, Hou Helei
肿瘤
卵巢癌
发表日期：2025
文献求助 收藏

Next-generation sequencing identifies potential mechanisms of primary resistance to trastuzumab-containing therapies in HER2-positive gastric cancer: Analysis based on real-world data and online databases

新一代测序技术揭示了HER2阳性胃癌对含曲妥珠单抗疗法产生原发性耐药的潜在机制：基于真实世界数据和在线数据库的分析

期刊:Human Vaccines & Immunotherapeutics
影响因子:3.5
doi:10.1080/21645515.2025.2555502
Zhang, Xuchen; Liu, Ning; Song, Shanai; Zhang, Chuantao; Li, Tianjun; Song, Wei; Huang, Shusheng; Chen, Yunqing; Yan, Weihua; Zhan, Jinfeng; Wang, Huiyun; Cui, Jiali; Jiang, Man; Hou, Helei
胃癌
肿瘤
肿瘤免疫
HER2
Sequencing
发表日期：2025
文献求助 收藏

A case report: Achieving complete response in synchronous primary lung and tongue squamous cell carcinomas through the integration of albumin-bound paclitaxel, cisplatin, and tislelizumab

病例报告：通过整合白蛋白结合型紫杉醇、顺铂和替雷利珠单抗治疗同步原发性肺癌和舌鳞状细胞癌，实现完全缓解

期刊:Human Vaccines & Immunotherapeutics
影响因子:3.5
doi:10.1080/21645515.2025.2593104
Huang, Xiao; Ma, Ying; Wang, Huiyun; Song, Shanai; Li, Tianjun; Zhang, Chuantao; Hou, Helei
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Efficacy and safety of neoadjuvant treatment with chemotherapy and immune checkpoint blockades for potentially resectable gastric cancer: A retrospective study

新辅助化疗联合免疫检查点阻断治疗潜在可切除胃癌的疗效和安全性：一项回顾性研究

期刊:Human Vaccines & Immunotherapeutics
影响因子:3.5
doi:10.1080/21645515.2025.2550096
Wang, Huiyun; Zhang, Xuchen; Tian, Yulong; Jiang, Haitao; Liu, Ning; Zhan, Jinfeng; Chen, Yunqing; Song, Shanai; Huang, Xiao; Jiang, Man; Zhang, Chuantao; Hou, Helei
胃癌
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2025
文献求助 收藏